(Q44423321)

English

Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer

scientific article published on March 13, 2003

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

multiple drug resistance

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12721757

29 December 2023

1 reference

10.1007/S00280-003-0573-4

https://api.crossref.org/works/10.1007/S00280-003-0573-4

29 December 2023

1 reference

10.1007/S00280-003-0573-4

https://api.crossref.org/works/10.1007/S00280-003-0573-4

29 December 2023

4

object named as

Tomasz M. Beer

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12721757

29 December 2023

author name string

Albert Einstein

2

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Richard Lush

3

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Yoo-Joung Ko

5

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Glenn Bubley

7

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Varun Garg

9

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Ene Ette

10

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Randall P. Rago

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12721757

29 December 2023

W. David Henner

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12721757

29 December 2023

Elizabeth A. Merica

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12721757

29 December 2023

Matthew W. Harding

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12721757

29 December 2023

William S. Dalton

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12721757

29 December 2023

language of work or name

1 reference

based on heuristic

inferred from title

publication date

13 March 2003

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

51

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

297-305

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Biochemical, cellular, and pharmacological aspects of the multidrug transporter

1

1 reference

10.1007/S00280-003-0573-4

https://api.crossref.org/works/10.1007/S00280-003-0573-4

29 December 2023

Potentiation by estramustine of the cytotoxic effect of vinblastine and doxorubicin in prostatic tumor cells

2

1 reference

10.1007/S00280-003-0573-4

https://api.crossref.org/works/10.1007/S00280-003-0573-4

29 December 2023

Expression of the multidrug resistance gene in human prostate cancer

3

1 reference

10.1007/S00280-003-0573-4

https://api.crossref.org/works/10.1007/S00280-003-0573-4

29 December 2023

A family of drug transporters: the multidrug resistance-associated proteins.

4

1 reference

10.1007/S00280-003-0573-4

https://api.crossref.org/works/10.1007/S00280-003-0573-4

29 December 2023

Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance.

5

1 reference

10.1007/S00280-003-0573-4

https://api.crossref.org/works/10.1007/S00280-003-0573-4

29 December 2023

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

7

1 reference

10.1007/S00280-003-0573-4

https://api.crossref.org/works/10.1007/S00280-003-0573-4

29 December 2023

Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells

8

1 reference

10.1007/S00280-003-0573-4

https://api.crossref.org/works/10.1007/S00280-003-0573-4

29 December 2023

Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: a decade of progress?

10

1 reference

10.1007/S00280-003-0573-4

https://api.crossref.org/works/10.1007/S00280-003-0573-4

29 December 2023

Pharmacokinetics and metabolism of mitoxantrone. A review

12

1 reference

10.1007/S00280-003-0573-4

https://api.crossref.org/works/10.1007/S00280-003-0573-4

29 December 2023

Clinical trials of P-glycoprotein reversal in solid tumours

13

1 reference

10.1007/S00280-003-0573-4

https://api.crossref.org/works/10.1007/S00280-003-0573-4

29 December 2023

Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP

15

1 reference

10.1007/S00280-003-0573-4

https://api.crossref.org/works/10.1007/S00280-003-0573-4

29 December 2023

Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro

16

1 reference

10.1007/S00280-003-0573-4

https://api.crossref.org/works/10.1007/S00280-003-0573-4

29 December 2023

Structural, mechanistic and clinical aspects of MRP1.

17

1 reference

10.1007/S00280-003-0573-4

https://api.crossref.org/works/10.1007/S00280-003-0573-4

29 December 2023

Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer

18

1 reference

10.1007/S00280-003-0573-4

https://api.crossref.org/works/10.1007/S00280-003-0573-4

29 December 2023

Expression of two multidrug resistance genes in human prostatic carcinomas

19

1 reference

10.1007/S00280-003-0573-4

https://api.crossref.org/works/10.1007/S00280-003-0573-4

29 December 2023

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

20

1 reference

10.1007/S00280-003-0573-4

https://api.crossref.org/works/10.1007/S00280-003-0573-4

29 December 2023

Demonstration of MDR1 P-glycoprotein isoform expression in benign and malignant human prostate cells by isoform-specific monoclonal antibodies.

21

1 reference

10.1007/S00280-003-0573-4

https://api.crossref.org/works/10.1007/S00280-003-0573-4

29 December 2023

Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer

22

1 reference

10.1007/S00280-003-0573-4

https://api.crossref.org/works/10.1007/S00280-003-0573-4

29 December 2023

MDR expression in normal tissues. Pharmacologic implications for the clinical use of P-glycoprotein inhibitors.

23

1 reference

10.1007/S00280-003-0573-4

https://api.crossref.org/works/10.1007/S00280-003-0573-4

29 December 2023

Chemotherapy for patients with advanced prostate carcinoma: a new option for therapy

24

1 reference

10.1007/S00280-003-0573-4

https://api.crossref.org/works/10.1007/S00280-003-0573-4

29 December 2023

MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS

25

1 reference

10.1007/S00280-003-0573-4

https://api.crossref.org/works/10.1007/S00280-003-0573-4

29 December 2023

Treatment of locally advanced prostate cancer: is chemotherapy the next step?

26

1 reference

10.1007/S00280-003-0573-4

https://api.crossref.org/works/10.1007/S00280-003-0573-4

29 December 2023

Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin

27

1 reference

10.1007/S00280-003-0573-4

https://api.crossref.org/works/10.1007/S00280-003-0573-4

29 December 2023

Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer

28

1 reference

10.1007/S00280-003-0573-4

https://api.crossref.org/works/10.1007/S00280-003-0573-4

29 December 2023

Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP.

29

1 reference

10.1007/S00280-003-0573-4

https://api.crossref.org/works/10.1007/S00280-003-0573-4

29 December 2023

Expression of the gene for the multidrug resistance-associated protein in human prostate tissue

30

1 reference

10.1007/S00280-003-0573-4

https://api.crossref.org/works/10.1007/S00280-003-0573-4

29 December 2023

Multidrug resistance in androgen-independent growing rat prostate carcinoma cells is mediated by P-glycoprotein

32

1 reference

10.1007/S00280-003-0573-4

https://api.crossref.org/works/10.1007/S00280-003-0573-4

29 December 2023

Optimal two-stage designs for phase II clinical trials

33

1 reference

10.1007/S00280-003-0573-4

https://api.crossref.org/works/10.1007/S00280-003-0573-4

29 December 2023

Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer

34

1 reference

10.1007/S00280-003-0573-4

https://api.crossref.org/works/10.1007/S00280-003-0573-4

29 December 2023

P-glycoprotein binding and modulation of the multidrug-resistant phenotype by estramustine

36

1 reference

10.1007/S00280-003-0573-4

https://api.crossref.org/works/10.1007/S00280-003-0573-4

29 December 2023

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

38

1 reference

10.1007/S00280-003-0573-4

https://api.crossref.org/works/10.1007/S00280-003-0573-4

29 December 2023

Expression of multidrug resistance related proteins and proliferative activity is increased in advanced clinical prostate cancer

40

1 reference

10.1007/S00280-003-0573-4

https://api.crossref.org/works/10.1007/S00280-003-0573-4

29 December 2023

Mitoxantrone. A review of its pharmacology and clinical efficacy in the management of hormone-resistant advanced prostate cancer

41

1 reference

10.1007/S00280-003-0573-4

https://api.crossref.org/works/10.1007/S00280-003-0573-4

29 December 2023

Modulation of the function of P-glycoprotein by estramustine.

43

1 reference

10.1007/S00280-003-0573-4

https://api.crossref.org/works/10.1007/S00280-003-0573-4

29 December 2023

Identifiers

10.1007/S00280-003-0573-4

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44423321&oldid=2206636838"